ArticleBMC oral health2026
Prognostic factor analysis of oral and maxillofacial Langerhans cell histiocytosis based on clinical findings and tumour microenvironment.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the clinical prognostic factors of oral and maxillofacial Langerhans cell histiocytosis (LCH-OMF) and the dynamics of regulatory T (Treg) cells and M2 macrophages.
methodsWe retrospectively analysed nine patients who were definitively diagnosed with LCH-OMF and examined clinical factors including age, sex, disease type, lesion site, clinical findings, the presence or absence of central nervous system (CNS) risk lesions, other organ lesions, treatment methods and prognosis. Immunohistochemical and fluorescent immunohistochemical analyses were performed to investigate prognostic factors from a cell biological perspective regarding the mechanism of onset in these patients.
resultsNone of the nine patients followed the previously reported clinical prognostic patterns, and no patient with lesions in cranio-maxillofacial bones within the CNS risk region developed CNS-related disease. One patient had multi-system LCH with risk organ involvement (MS [RO +]) and the poorest prognosis; in this case, an increase in Tregs in the LCH lesion may have caused tumour immunosuppression, suggesting an association with disease severity. Findings from this patient suggested that interleukin (IL)-10 secretion by M2 macrophages may be an initiating factor in the mechanisms that regulate tumour growth; however, this interpretation is hypothesis-generating and based on a small number of cases.
conclusionAssessing the prognosis of LCH-OMF requires a comprehensive consideration of the disease type, age, CNS-risk regions, risk organs, acute systemic inflammatory response, and skin involvement. A better understanding of IL-10 derived from Tregs and M2 macrophages in LCH-OMF and in LCH overall may enhance our comprehension of inflammatory dysregulation and Langerhans cell progression in LCH and could help to identify potential treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.